Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › TRVI

SILVERARC CAPITAL MANAGEMENT, LLC position in TRVI

TREVI THERAPEUTICS INC · Health Care

SILVERARC CAPITAL MANAGEMENT, LLC reported holding 678,095 shares of TRVI (TREVI THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$12.6M, representing 1.48% of its reported portfolio and ranking #21 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed TRVI holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)678.10K sh
Reported value held$12.65M
Portfolio Weight1.48%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How SILVERARC CAPITAL MANAGEMENT, LLC's TRVI position evolved

SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in TRVI in Q3 2023 at 927,415 shares (US$2.0M). The position peaked in Q2 2026 at 678,095 shares, worth US$12.6M. Across 12 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 4 time(s), trimmed it 6 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 678,095 shares valued at US$12.6M — an increase of 166,968 shares quarter over quarter.. Notable position changes include a 43% trim in Q3 2024 (shares rose 23% over the following quarter), a 52% increase in Q4 2024 (shares rose 53% over the following quarter), a 33% increase in Q2 2026 (shares fell 23% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 927.41K $2.02M New
Q4 2023 863.88K $1.16M Reduce
Q1 2024 844.24K $2.91M Reduce
Q2 2024 844.24K $2.52M Hold
Q3 2024 482.57K $1.61M Reduce
Q4 2024 734.23K $3.03M Add
Q1 2025 530.00K $3.33M Reduce
Q2 2025 539.59K $2.95M Add
Q3 2025 588.79K $5.39M Add
Q4 2025 541.24K $6.78M Reduce
Q1 2026 511.13K $6.10M Reduce
Q2 2026 678.10K $12.65M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TRVI and 13F data

TRVI (TREVI THERAPEUTICS INC) is a Health Care company. 64 other funds we track also report a position in TRVI — the largest reported positions include NEA Management Company, LLC (US$246.6M), Frazier Life Sciences Management, L.P. (US$185.4M), Vivo Capital, LLC (US$95.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TRVI

All TRVI fund holders →

FAQ

How long has SILVERARC CAPITAL MANAGEMENT, LLC held TRVI?

SILVERARC CAPITAL MANAGEMENT, LLC has disclosed TRVI holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in TRVI?

As of Q2 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 678.10K shares of TRVI (TREVI THERAPEUTICS INC), valued at $12.65M, representing 1.48% of its reported portfolio and ranking #21.

Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling TRVI?

In the latest 13F filing (Q2 2026), SILVERARC CAPITAL MANAGEMENT, LLC increased its position in TRVI. The position peaked in Q2 2026 at 678.10K shares.

Which other funds hold TRVI?

Other major institutional holders of TRVI include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., Vivo Capital, LLC, among 64 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.